Research and Treatment Progress of Capmatinib in Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) cases account for the vast majority of liver cancer with high mortality. There is no particular therapy for HCC, and it has been claimed that only around 25% of individuals with HCC are candidates for curative surgery. The only drug approved FDA for HCC is Sorafenib, however it is prone to drug resistance. Abnormal c-met activity is linked to Tumorigenesis and tumor metastasis, implying that inhibiting relevant pathway might be therapeutic. HGF/c-Met pathway is related HCC exacerbation and metastasis, abnormal met signaling leads to activated downstream pathways and causes tumorigenesis. also, the HGF/c-Met induces the VEGF pathway to enhance tumor angiogenesis. Met is becoming a key target in HCC treatment, especially in advanced patients. As a small molecure met inhibitor, Capmatinib has high sensitivity of Met receptor, it can be absorbed rapidly, with good pharmacokinetic characteristics. It has good antitumor activity in clinical efficacy, well toleranced and with slight side effects. In addition, it is irrelevant to food which means patients have the same concentration of capmatinib in plasma regardless of their eating habits, which will be an effective and safe treatment strategy for HCC. Application of Capmatinib as HCC target treatment remains popular in HCC research, and clinical trials designed in diverse dimensions are ongoing to study the benefits of capmatinib.